SBIO.L vs. GNOG.L
SBIO.L (Invesco Nasdaq Biotech UCITS ETF) and GNOG.L (Global X Genomics & Biotechnology UCITS ETF) are both Health & Biotech Equities funds - SBIO.L tracks the NASDAQ Biotechnology TR USD while GNOG.L tracks the MSCI World/Health Care NR USD. Both are passively managed. Over the past 3 years, SBIO.L returned 12.99%/yr vs 0.67%/yr for GNOG.L. Their correlation of 0.83 suggests significant overlap in exposure. SBIO.L charges 0.40%/yr vs 0.50%/yr for GNOG.L.
Performance
SBIO.L vs. GNOG.L - Performance Comparison
Loading charts...
Different Trading Currencies
SBIO.L is traded in USD, while GNOG.L is traded in GBP. To make them comparable, the GNOG.L values have been converted to USD using the latest available exchange rates.
Returns By Period
In the year-to-date period, SBIO.L achieves a 4.34% return, which is significantly lower than GNOG.L's 12.00% return.
SBIO.L
- 1D
- 3.10%
- 1M
- 0.91%
- YTD
- 4.34%
- 6M
- 2.82%
- 1Y
- 41.33%
- 3Y*
- 12.99%
- 5Y*
- 4.66%
- 10Y*
- 7.49%
GNOG.L
- 1D
- 5.75%
- 1M
- 12.69%
- YTD
- 12.00%
- 6M
- 10.28%
- 1Y
- 57.88%
- 3Y*
- 0.67%
- 5Y*
- —
- 10Y*
- —
SBIO.L vs. GNOG.L - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
SBIO.L Invesco Nasdaq Biotech UCITS ETF | 4.34% | 32.89% | -2.00% | 6.14% | -11.85% | -5.97% |
GNOG.L Global X Genomics & Biotechnology UCITS ETF | 12.00% | 20.48% | -18.36% | -6.67% | -37.25% | -10.07% |
Correlation
The correlation between SBIO.L and GNOG.L is 0.81, indicating a strong positive relationship between their price movements. Combining them offers limited diversification - they tend to fall together during downturns.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.81 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.82 |
Correlation (All Time) Calculated using the full available price history since Nov 5, 2021 | 0.83 |
The correlation between SBIO.L and GNOG.L has been stable across timeframes, ranging from 0.81 to 0.83 - a consistent structural relationship.
SBIO.L vs. GNOG.L - Sectors Allocation Comparison
Sectors
SBIO.L
GNOG.L
Healthcare
Basic Materials
-
-
Communication Services
-
-
Consumer Cyclical
-
-
Consumer Defensive
-
-
Energy
-
-
Financial Services
-
-
Industrials
-
-
Real Estate
-
-
Technology
-
Utilities
-
-
Healthcare
SBIO.L
GNOG.L
Basic Materials
SBIO.L
-
GNOG.L
-
Communication Services
SBIO.L
-
GNOG.L
-
Consumer Cyclical
SBIO.L
-
GNOG.L
-
Consumer Defensive
SBIO.L
-
GNOG.L
-
Energy
SBIO.L
-
GNOG.L
-
Financial Services
SBIO.L
-
GNOG.L
-
Industrials
SBIO.L
-
GNOG.L
-
Real Estate
SBIO.L
-
GNOG.L
-
Technology
SBIO.L
-
GNOG.L
Utilities
SBIO.L
-
GNOG.L
-
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
SBIO.L vs. GNOG.L — Risk / Return Rank
SBIO.L
GNOG.L
SBIO.L vs. GNOG.L - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Invesco Nasdaq Biotech UCITS ETF (SBIO.L) and Global X Genomics & Biotechnology UCITS ETF (GNOG.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| SBIO.L | GNOG.L | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.06 | ||
| Sortino ratioReturn per unit of downside risk | +0.15 | ||
| Omega ratioGain probability vs. loss probability | 1.35 | 1.33 | +0.01 |
| Calmar ratioReturn relative to maximum drawdown | 5.38 | 3.05 | +2.34 |
| Martin ratioReturn relative to average drawdown | 16.56 | 8.31 | +8.25 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| SBIO.L | GNOG.L | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 2.09 | 2.04 | +0.06 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.22 | — | — |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.34 | — | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.27 | -0.34 | +0.61 |
Drawdowns
SBIO.L vs. GNOG.L - Drawdown Comparison
The maximum SBIO.L drawdown since its inception was -39.44%, smaller than the maximum GNOG.L drawdown of -69.29%. Use the drawdown chart below to compare losses from any high point for SBIO.L and GNOG.L.
Loading charts...
Drawdown Indicators
| SBIO.L | GNOG.L | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -39.44% | -69.29% | +29.85% |
Max Drawdown (1Y)Largest decline over 1 year | -7.64% | -18.90% | +11.26% |
Max Drawdown (3Y)Largest decline over 3 years | -26.88% | -46.70% | +19.82% |
Max Drawdown (5Y)Largest decline over 5 years | -38.33% | — | — |
Max Drawdown (10Y)Largest decline over 10 years | -38.33% | — | — |
Current DrawdownCurrent decline from peak | -2.84% | -42.38% | +39.54% |
Average DrawdownAverage peak-to-trough decline | -16.83% | -47.52% | +30.69% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 2.49% | 6.95% | -4.46% |
Volatility
SBIO.L vs. GNOG.L - Volatility Comparison
The current volatility for Invesco Nasdaq Biotech UCITS ETF (SBIO.L) is 6.55%, while Global X Genomics & Biotechnology UCITS ETF (GNOG.L) has a volatility of 8.37%. This indicates that SBIO.L experiences smaller price fluctuations and is considered to be less risky than GNOG.L based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| SBIO.L | GNOG.L | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.55% | 8.37% | -1.82% |
Volatility (6M)Calculated over the trailing 6-month period | 15.27% | 20.65% | -5.38% |
Volatility (1Y)Calculated over the trailing 1-year period | 19.67% | 28.31% | -8.64% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 21.21% | 32.72% | -11.51% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 22.23% | 32.72% | -10.49% |
SBIO.L vs. GNOG.L - Expense Ratio Comparison
SBIO.L has a 0.40% expense ratio, which is lower than GNOG.L's 0.50% expense ratio.
Dividends
SBIO.L vs. GNOG.L - Dividend Comparison
Neither SBIO.L nor GNOG.L has paid dividends to shareholders.
Frequently Asked Questions
SBIO.L and GNOG.L have a correlation of 0.81, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
On fees, SBIO.L is cheaper at 0.40% per year. The better choice depends on whether you care most about return, fees, risk, or income.
SBIO.L is cheaper with a 0.40% expense ratio, compared with 0.50% for GNOG.L.
SBIO.L tracks NASDAQ Biotechnology TR USD, while GNOG.L tracks MSCI World/Health Care NR USD. They also come from different issuers: Invesco and Global X. Their fees differ too: 0.40% for SBIO.L and 0.50% for GNOG.L.
Find the right allocation for SBIO.L and GNOG.L
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer